Nektar Therapeutics Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Nektar Therapeutics (NKTR) reported third-quarter 2026 results characterized by a net loss of $55.7 million, an increase from the $35.5 million loss in the prior-year period. This widening loss was primarily driven by elevated research and development expenses totaling $44.1 million as the company advances its ZENITH AD and ZENITH AA clinical programs. Total revenue for the quarter stood at $9.4 million, consisting entirely of noncash royalty revenue. Despite the net loss, Nektar maintains a robust liquidity position with $952.9 million in cash and investments as of September 30, 2026. Management expects to end the year with more than $840 million in cash, meeting or exceeding previous guidance. The company is heavily focused on its Phase 3 registrational programs for atopic dermatitis and alopecia areata, targeting significant market opportunities in these therapeutic areas.
Tickers: $NKTR
Topics: Cash Guidance Clinical Trials Net Loss R&D Expense Revenue